Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine. The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking. Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared with nonsmokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties. Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, changes in patients’ use of nicotine/tobacco products can influence metabolism of BZDs.51”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [51]
Citations
Cites
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Smoking and Mental Illness: A Population-Based Prevalence Study
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000) · JAMA · doi:10.1001/jama.284.20.2606 · Cited by 2,508
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Toxicology. The basic science of poisons
(1976) · Food and Cosmetics Toxicology · doi:10.1016/s0015-6264(76)80311-2 · Cited by 708
The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz, U., Avant, G. R., Hoyumpa, A., Schenker, S., & Wilkinson, G. R. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107938 · Cited by 696
Drug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
Enzyme induction in the cytochrome P-450 system
Okey, A. B. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90030-6 · Cited by 625
Olanzapine: Pharmacokinetic and Pharmacodynamic Profile
Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., & Beasley, C. M. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937030-00001 · Cited by 544
Applied therapeutics; the clinical use of drugs
(1990) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(90)90630-5 · Cited by 399
Research works printed but not linked: 8
- Shimada, 1994, J Pharmacol Exp Ther, 270, 414
- Luczynska, 1983, Methods Find Exp Clin Pharmacol, 5, 479
- Miller, 1990, Clin Pharm, 9, 125
- Vinarova, 1984, Biol Psychiatry, 19, 1265
- Stimmel, 1983, J Clin Psychiatry, 44, 420
- Kondo, 1996, Psychopharmacology, 127, 311, 10.1007/bf02806008 · doi:10.1007/bf02806008
- Norman, 1981, Clin Pharmacol, 229-, 33
- Desmond, 1979, N Engl J Med, 300, 199
Cited by
Effects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801
Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Wootton, R. E., Richmond, R. C., Stuijfzand, B. G., Lawn, R. B., Sallis, H. M., Taylor, G. M. J., Hemani, G., Jones, H. J., Zammit, S., Davey Smith, G., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291719002678 · Cited by 587
Comorbidity of Severe Psychotic Disorders With Measures of Substance Use
Hartz, S. M., Pato, C. N., Medeiros, H., Cavazos-Rehg, P., Sobell, J. L., Knowles, J. A., Bierut, L. J., & Pato, M. T. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3726 · Cited by 395
Addressing tobacco among individuals with a mental illness or an addiction
Williams, J. M., & Ziedonis, D. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.03.009 · Cited by 359
Metadata
- Authors
- Desai, H. D., Seabolt, J., & Jann, M. W.
- Affiliations
- Mercer University (US)
- University of Illinois Chicago (US)
- Corresponding author
- Jann, Michael W.
- ORCID
- Jann, Michael W.
- Venue
- CNS Drugs
- Published
- 2001
- Volume
- 15
- Issue
- 6
- Pages
- 469-494
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W179281078
- Cited by
- 253
- References
- 92
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 28 · 2019: 13 · 2018: 7 · 2017: 14 · 2016: 12 · 2015: 13 · 2014: 7 · 2013: 11 · 2012: 9
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- cigarette smoking, psychotropic drugs, drug metabolism, polycyclic aromatic hydrocarbons, cytochrome P450 induction, aryl hydrocarbon hydroxylase, drug-drug interactions, imipramine, clomipramine, fluvoxamine, trazodone, amitriptyline, nortriptyline, bupropion, antipsychotic drugs, chlorpromazine, clozapine, benzodiazepines, carbamazepine, plasma drug concentration
- MeSH terms
- Animals, Mental Disorders, Drug Interactions, Humans, Psychotropic Drugs, Smoking
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective. https://app.cochat.ai/papers/10.2165/00023210-200115060-00005
- The paper
- Desai, H. D., Seabolt, J., & Jann, M. W. (2001). Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective. CNS Drugs. https://doi.org/10.2165/00023210-200115060-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.